What is Xeltis?
Headquartered with operations spanning the Netherlands and the United States, Xeltis operates at the intersection of advanced materials science and cardiovascular medicine. The company specializes in restorative devices, including heart valves and small-diameter blood vessels, which are engineered to integrate with the patient's own body to restore natural function. Unlike traditional prosthetic implants, Xeltis' investigational technology aims to reduce long-term complications by enabling the body to regenerate its own tissue. This unique approach positions the company as a disruptive force in the medical device sector, particularly for applications in coronary artery bypass grafting and hemodialysis vascular access.
How much funding has Xeltis raised?
Xeltis has raised a total of $113.4M across 4 funding rounds:
Series B
$3.3M
Series C
$52.8M
Series D
$34M
Other Financing Round
$23.3M
Series B (2015): $3.3M with participation from Life Sciences Partners, VI Partners, and Kurma Partners
Series C (2017): $52.8M led by VI Partners, Kurma Partners, Ysios Capital, and Life Sciences Partners
Series D (2023): $34M supported by Invest-NL, EQT Life Sciences, and Grand Pharmaceutical Group
Other Financing Round (2026): $23.3M featuring VI Partners, EQT, The European Innovation Council, Invest-NL, and DaVita
Key Investors in Xeltis
VI Partners
VI Partners is the longest-established Swiss VC firm, supporting innovative healthcare and technology companies for over two decades with a focus on long-term value creation.
Kurma Partners
Kurma Partners is a prominent European venture capital firm specializing in healthcare and biotechnology, transforming disruptive scientific discoveries into advanced medical solutions.
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide to address high unmet medical needs.
What's next for Xeltis?
With the recent influx of capital, Xeltis is well-positioned to accelerate its clinical trial programs and refine its manufacturing processes for its investigational restorative conduits. The company's strategic roadmap focuses on navigating the complex regulatory landscape required for market approval while expanding its footprint in the global cardiovascular market. By leveraging the expertise of its diverse investor base, Xeltis aims to transition from a clinical-stage innovator to a commercial-stage leader, ultimately providing clinicians with a new standard of care for patients suffering from severe cardiovascular and renal conditions.
See full Xeltis company page
